文献速递鼻科

贝伐珠单抗注射治疗遗传性出血性毛细血管扩张症患者电凝术中鼻出血的随机对照双盲临床试验

Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.
PubMed 文献 · Int Forum Allergy Rhinol · 2022-01-19

这项单中心随机双盲安慰剂对照试验纳入39例接受鼻部毛细血管扩张双极电凝术的遗传性出血性毛细血管扩张症患者,比较黏膜下注射生理盐水与贝伐珠单抗对鼻出血严重程度及生活质量的影响。贝伐珠单抗组在术后1、2、4、6个月ESS较基线下降,其相对于生理盐水的附加获益在1、2、4个月超过最小临床重要差异但差异无统计学意义。作者认为单次黏膜下贝伐珠单抗注射可能带来长达4个月的额外临床获益。

要点

  • 贝伐珠单抗组ESS较基线在术后1、2、4、6个月均下降。
  • 贝伐珠单抗相对生理盐水的附加获益在1、2、4个月超过MCID 0.71,但差异无统计学意义。
  • 作者认为单次黏膜下贝伐珠单抗可能带来长达4个月的额外临床获益。

核心结论

  • 与单纯电凝相比,加用单次黏膜下贝伐珠单抗注射可能与长达4个月的额外临床获益相关。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,2014年至2019年在单一机构开展。
  • 39例计划接受鼻部毛细血管扩张双极电凝术的患者随机接受黏膜下生理盐水或贝伐珠单抗注射。
  • 术前及术后1、2、4、6个月采用ESS和SF-12评估鼻出血严重程度与生活质量。
  • ESS的最小临床重要差异(MCID)报告为0.71。

主要发现

  • 39例入组患者中37例(94.9%)完成研究。
  • 生理盐水组ESS较基线在术后1个月下降1.2(p=0.01)、4个月下降1.2(p=0.05)。
  • 贝伐珠单抗组ESS较基线在术后1个月下降2.3(p<0.001)、2个月下降2.3(p<0.001)、4个月下降2.0(p=0.003)、6个月下降1.3(p=0.05)。
  • 贝伐珠单抗相对生理盐水的附加获益在1、2、4个月超过MCID,但差异无统计学意义。

临床怎么用

  • 作者认为,在电凝术时加用单次黏膜下贝伐珠单抗注射可能为遗传性出血性毛细血管扩张症患者带来长达4个月的额外临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given its role in the disease pathophysiology, inhibition of vascular endothelial growth factor (VEGF)-mediated angiogenesis has received attention as a potential strategy to reduce epistaxis associated with hereditary hemorrhagic telangiectasia (HHT). In this study we evaluated the efficacy of a submucosal injection of bevacizumab, a VEGF inhibitor, in reducing the severity of epistaxis and improving quality of life when given at the time of operative electrocautery. METHODS: This randomized, double-blinded, placebo-controlled trial was conducted at a single institution from 2014 to 2019. Patients scheduled to undergo operative bipolar electrocautery of nasal telangiectasias were randomized to receive a submucosal injection of saline or bevacizumab at time of surgery. Surveys to assess epistaxis severity and quality of life (QOL), including the Epistaxis Severity Score (ESS) and the 12-item Short Form (SF-12), were administered preoperatively and at 1, 2, 4, and 6 months postoperatively. The minimal clinically important difference (MCID) of the ESS instrument is reported to be 0.71. RESULTS: Of 39 patients enrolled, 37 (94.9%) completed the study. The saline group demonstrated a reduced ESS vs baseline at 1 (-1.2; p = 0.01) and 4 (-1.2; p = 0.05) months postprocedure. The bevacizumab group demonstrated a reduced ESS score vs baseline at 1 (-2.3; p < 0.001), 2 (-2.3; p < 0.001), 4 (-2.0; p = 0.003), and 6 (-1.3; p = 0.05) months postprocedure. The additive benefit of bevacizumab over saline exceeded the MCID at 1, 2, and 4 months, but the difference was not statistically significant. CONCLUSION: The addition of a single treatment of submucosal bevacizumab may be associated with additional clinically meaningful benefit for up to 4 months when compared with electrocautery alone.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Khanwalkar AR, Rathor A, Read AK, et al. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization. Int Forum Allergy Rhinol. 2022. PMID: 34989143. doi:10.1002/alr.22961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。